ArticleBMC infectious diseases2025
Utility of TaqMan Array Cards for detection of acute febrile illness etiologies in patients suspected of viral hemorrhagic fever infections.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Etiologies of community-acquired febrile illness identified by TaqMan Array Card qPCR on blood samples: a systematic review and meta-analysis.Journal of clinical microbiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDue to the difficulty in attributing a causative agent to acute febrile illnesses (AFI), multi-pathogen diagnostic tools should be prioritized in low-resource settings. A previously developed AFI-TaqMan Array Card (AFI-TAC), capable of detecting 26 pathogens within 2 h of nucleic acid extraction, was evaluated in Uganda.
methodsA cross-sectional retrospective study design was employed and utilized 182 viral hemorrhagic fever (VHF)-negative samples collected from Uganda, DRC, South Sudan and Kenya during routine surveillance from August 2018- March, 2019. These samples were tested on AFI-TAC targeting 17 viral, 8 bacterial and 3 protozoal pathogens known to cause fever. Patients with a body temperature of ≥ 38 °C, were bleeding, and had any other febrile symptoms were included. Previously confirmed VHF positive samples were used for assay verification.
resultsOverall, 7 pathogens were detected in 59 samples (32.42%) as follows: Plasmodium spp. (n = 49, 26.92%), non-typhoidal Salmonella (n = 3, 1.65%), Yellow Fever (YF) virus (n = 2, 1.10%), Salmonella enterica serovar typhi (n = 2, 1.10%), Leptospira spp (n = 1, 0.55%), Streptococcus pneumoniae (n = 1, 0.55%) and Rickettsia spp. (n = 1, 0.55%). Final outcome (alive vs. dead) as abstracted from case report forms differed significantly by pathogen category (p = 0.002) was significantly associated with assay positivity. We compared outcome across pathogen categories using a chi-square/Fisher's exact test, as appropriate, reporting p-values (Table 2). Cough was the only clinical symptom significantly associated with Plasmodium infection (p = 0.016).
conclusionThe TAC is a feasible, readily adoptable diagnostic tool for use in Uganda and other sub-Saharan countries, particularly when incorporated into the national testing algorithm for differential diagnosis during AFI outbreaks and surveillance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.